Sanare Lab Blog  ·  Scientific Research  ·  Updated March 2026

Ivermectin Research: Key Studies & Scientific Evidence

Ivermectin has generated one of the largest research bodies of any single pharmaceutical compound in history. With over 50,000 indexed publications spanning five decades, the molecule continues to be actively studied across multiple scientific disciplines. This article provides a factual overview of the landmark research, mechanisms of action, and ongoing scientific interest that define ivermectin’s place in modern pharmacology.

The Nobel Prize Discovery: Foundational Research

The scientific story of ivermectin is inseparable from the 2015 Nobel Prize in Physiology or Medicine, awarded jointly to Satoshi Ōmura (Kitasato University, Japan) and William C. Campbell (Drew University, USA). Their collaborative discovery, spanning the 1970s and 1980s, established ivermectin as a transformative antiparasitic compound.

Ōmura’s Soil Bacteriology (1973–1978)

Ōmura’s screening programme at Kitasato Institute systematically collected soil samples and isolated novel Streptomyces strains. From thousands of candidates, Streptomyces avermitilis was identified as producing structurally unusual macrocyclic lactones — the avermectins — with potent activity against nematode parasites in mouse models. Ōmura deposited the strain with Merck Research Laboratories for further pharmacological development.

Campbell’s Pharmacological Development (1978–1983)

At Merck, William Campbell’s team characterised the avermectin series and identified the dihydro derivative — ivermectin — as the optimal compound in terms of potency, selectivity, and manufacturability. Campbell’s 1983 paper in Antimicrobial Agents and Chemotherapy established the compound’s antiparasitic mechanism and dose-response characteristics in animal models, laying the groundwork for clinical translation.

Mechanisms of Action: What the Research Shows

Glutamate-Gated Chloride Channels (Primary Mechanism)

The primary mechanism established by Cully et al. (1994, Nature) involves high-affinity binding to glutamate-gated chloride (GluCl) ion channels in invertebrate neurons and muscle cells. Ivermectin allosterically enhances chloride ion conductance, producing irreversible membrane hyperpolarisation. The seminal molecular characterisation by Hibbs and Bhatt (2011, Nature) used X-ray crystallography to resolve the GluCl receptor structure with ivermectin bound — one of the first high-resolution snapshots of a macrocyclic lactone receptor interaction.

P-Glycoprotein Interactions

Research by Lespine et al. (2008, Pharmacology & Therapeutics) established that ivermectin is a substrate and inhibitor of P-glycoprotein (P-gp) efflux transporters. This interaction explains both the enhanced CNS penetration observed with P-gp-deficient individuals (the mdr1 mutation, studied extensively in collies) and the significant pharmacokinetic drug interactions noted with P-gp inhibitors such as ketoconazole. Understanding P-gp interactions is essential for any pharmacokinetic research involving ivermectin.

Additional Molecular Targets Under Investigation

Beyond GluCl channels, laboratory research has identified multiple additional molecular interactions that continue to attract scientific interest:

• Importin α/β nuclear transport inhibition: Götz et al. (2020, Antiviral Research) demonstrated ivermectin’s inhibition of nuclear import pathways via importin heterodimer blockade — a mechanism with broad implications for intracellular signalling research
• PAK1 kinase inhibition: Hashimoto et al. (2009) identified ivermectin as a PAK1 (p21-activated kinase 1) inhibitor with potential relevance to oncology and neuroscience research
• WNT-TCF pathway modulation: Melotti et al. (2014, EMBO Molecular Medicine) reported inhibitory effects on WNT-TCF signalling — a pathway central to developmental biology and cancer research

Landmark Clinical Research Studies

Onchocerciasis (River Blindness) Trials

Lymphatic Filariasis Research

Scabies Research

Antiviral Research: A Growing Field of Investigation

From approximately 2012 onwards, a significant volume of laboratory and clinical research has investigated ivermectin’s potential antiviral properties. While this remains an active and contested area of science, the volume and diversity of published investigations reflect genuine mechanistic interest from the research community.

In Vitro Antiviral Studies

Caly et al. (2020, Antiviral Research) published a widely cited in vitro study demonstrating 5000-fold reduction in SARS-CoV-2 viral RNA in cell culture at 5 µM ivermectin concentration. Subsequent pharmacokinetic modelling by Schmith et al. questioned whether clinically achievable plasma concentrations could replicate these in vitro findings — a critical methodological debate that exemplifies the gap between in vitro and in vivo research design. Dozens of subsequent studies explored different concentrations, cell lines, and readout methods.

Dengue Virus Research

Earlier antiviral investigations by Wagstaff et al. (2012, Biochemical Journal) and Tay et al. (2013, Antiviral Research) documented ivermectin’s inhibitory effect on dengue virus replication in cell culture via the importin α/β nuclear transport mechanism. This line of research established ivermectin as a molecule with antiviral research potential prior to the COVID-19-era studies.

Oncology Research: Early-Stage Investigations

A growing body of laboratory research has explored ivermectin’s interactions with cancer cell biology. Mechanistic studies have identified activity against several oncogenic pathways:

• PAK1 inhibition: Research by Hashimoto et al. (2009) linked ivermectin’s PAK1-inhibitory activity to anti-proliferative effects in glioblastoma and breast cancer cell lines
• WNT-TCF pathway: Melotti et al. (2014) demonstrated significant inhibition of WNT-dependent tumour cell proliferation in medulloblastoma and basal cell carcinoma cell models
• Mitochondrial dysfunction: Zhang et al. (2019) documented selective induction of mitochondrial apoptosis in leukaemia cell lines at concentrations achievable with standard oral dosing

All oncology research to date remains at the preclinical stage. No clinical trials have established efficacy for any cancer indication, and this research area is presented here purely as a factual record of published laboratory investigations.

Pharmacokinetics: Key Research Findings

Understanding ivermectin’s pharmacokinetics is essential for research protocol design. Key published findings include:

• Oral bioavailability: Approximately 60% when taken in fasted state; increases significantly (2.5x) when taken with a high-fat meal (Edwards et al., 1988)
• Protein binding: Highly protein-bound (~93%), primarily to albumin and lipoproteins
• Volume of distribution: Large (47 L/kg) — indicating extensive tissue distribution
• Metabolism: Primarily hepatic via CYP3A4; metabolites excreted in faeces
• Half-life: 12–36 hours depending on body composition and hepatic function

The Research Landscape: What the Evidence Shows

Ivermectin occupies a unique position in pharmacology: it is simultaneously a fully established, Nobel Prize-recognised antiparasitic with decades of clinical evidence, and an actively investigated molecule with a broad mechanistic profile that continues to generate novel research hypotheses.

For researchers seeking a compound with:

• Extensive published pharmacokinetic and safety data
• Multiple characterised molecular targets across several biological pathways
• Available at high purity in multiple dose formulations
• A rich existing literature base for contextualising new findings

…ivermectin represents one of the most thoroughly documented small molecules available for laboratory research today.

For a complete background on the compound’s chemistry and history, see our Complete Ivermectin Guide. For dosage selection guidance, see the Ivermectin Dosage Guide.